Abstract
An acellular pertussis vaccine containing agglutinogens 2 and 3, pertussis toxin, and filamentous haemagglutinin was developed by the Centre for Applied Microbiology and Research in the UK. 188 infants were entered into a randomised blind trial and received either the acellular or a whole-cell vaccine, combined with diphtheria and tetanus toxoids, in a 3, 5, and 8-10 month schedule. Local reactions were similar in the two groups but significantly fewer infants had systemic symptoms after the acellular vaccine. Mean log-antibody titres to the agglutinogen and toxin components were higher with the acellular than with the whole-cell vaccine. Persistence of antibodies one year after the third dose was also better in the acellular group.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Bacterial / analysis*
-
Bacterial Vaccines / adverse effects
-
Bacterial Vaccines / classification
-
Bacterial Vaccines / immunology*
-
Diphtheria-Tetanus-Pertussis Vaccine / adverse effects
-
Diphtheria-Tetanus-Pertussis Vaccine / immunology*
-
Erythema / etiology
-
Evaluation Studies as Topic
-
Female
-
Fimbriae, Bacterial / immunology*
-
Hemagglutinins / immunology*
-
Humans
-
Immunization Schedule
-
Infant
-
Male
-
Pertussis Toxin*
-
Surveys and Questionnaires
-
Time Factors
-
Virulence Factors, Bordetella / immunology*
-
Whooping Cough / immunology*
-
Whooping Cough / prevention & control
Substances
-
Antibodies, Bacterial
-
Bacterial Vaccines
-
Diphtheria-Tetanus-Pertussis Vaccine
-
Hemagglutinins
-
Virulence Factors, Bordetella
-
Pertussis Toxin